Additionally, the 36-month beta value for FENC is 0.34. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for FENC is 22.97M and currently, short sellers hold a 8.12% ratio of that float. The average trading volume of FENC on November 28, 2024 was 104.48K shares.
FENC) stock’s latest price update
The stock price of Fennec Pharmaceuticals Inc (NASDAQ: FENC) has dropped by -0.50 compared to previous close of 6.04. Despite this, the company has seen a gain of 29.53% in its stock price over the last five trading days. globenewswire.com reported 2024-11-13 that RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company’s management will be available for one-on-one meetings throughout the event.
FENC’s Market Performance
FENC’s stock has risen by 29.53% in the past week, with a monthly rise of 25.47% and a quarterly rise of 8.68%. The volatility ratio for the week is 13.27% while the volatility levels for the last 30 days are 8.85% for Fennec Pharmaceuticals Inc The simple moving average for the past 20 days is 28.13% for FENC’s stock, with a -13.77% simple moving average for the past 200 days.
Analysts’ Opinion of FENC
Many brokerage firms have already submitted their reports for FENC stocks, with Cantor Fitzgerald repeating the rating for FENC by listing it as a “Overweight.” The predicted price for FENC in the upcoming period, according to Cantor Fitzgerald is $12 based on the research report published on November 22, 2022 of the previous year 2022.
CapitalOne, on the other hand, stated in their research note that they expect to see FENC reach a price target of $11. The rating they have provided for FENC stocks is “Overweight” according to the report published on September 07th, 2022.
Craig Hallum gave a rating of “Buy” to FENC, setting the target price at $14 in the report published on August 08th of the previous year.
FENC Trading at 28.08% from the 50-Day Moving Average
After a stumble in the market that brought FENC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.58% of loss for the given period.
Volatility was left at 8.85%, however, over the last 30 days, the volatility rate increased by 13.27%, as shares surge +34.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.13% upper at present.
During the last 5 trading sessions, FENC rose by +29.53%, which changed the moving average for the period of 200-days by -36.06% in comparison to the 20-day moving average, which settled at $4.69. In addition, Fennec Pharmaceuticals Inc saw -46.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FENC starting from Raykov Rosty, who sale 2,431 shares at the price of $4.31 back on Nov 04 ’24. After this action, Raykov Rosty now owns 66,432 shares of Fennec Pharmaceuticals Inc, valued at $10,478 using the latest closing price.
ROSTISLAV RAYKOV, the Director of Fennec Pharmaceuticals Inc, proposed sale 2,431 shares at $4.31 during a trade that took place back on Nov 04 ’24, which means that ROSTISLAV RAYKOV is holding shares at $10,478 based on the most recent closing price.
Stock Fundamentals for FENC
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.94 for the gross margin
The net margin for Fennec Pharmaceuticals Inc stands at -0.02. The total capital return value is set at 0.03.
Based on Fennec Pharmaceuticals Inc (FENC), the company’s capital structure generated 1.19 points at debt to capital in total, while cash flow to debt ratio is standing at 0.74. The debt to equity ratio resting at -6.21. The interest coverage ratio of the stock is 0.39.
Currently, EBITDA for the company is -12.36 million with net debt to EBITDA at -2.6. When we switch over and look at the enterprise to sales, we see a ratio of 3.16. The receivables turnover for the company is 3.84for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.80.
Conclusion
In conclusion, Fennec Pharmaceuticals Inc (FENC) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
